nach oben

Clinical Rheumatology

Erschienen in:

03.08.2017 | Review Article

Management of chikungunya arthritis

verfasst von: J. Kennedy Amaral Pereira, Robert T. Schoen

Erschienen in: Clinical Rheumatology | Ausgabe 10/2017

Einloggen, um Zugang zu erhalten

Abstract

Chikungunya fever (CHIKF) is an emerging viral infection that has spread widely, along with its Aedes vectors, throughout the tropics and beyond, causing explosive epidemics of both acute illness and persistent disabling arthritis. There is an urgent need to mitigate the devastating impact of this illness, through vector control, personal protection, and possibly vaccine development. There is also a need to improve treatment for both acute illness and chronic arthritis. In this review, we will review the emergence of CHIK, what is known about pathogenesis and clinical manifestations, and then focus on current understanding of how to treat individual patients, in particular, those who develop chronic arthritis.

Suhrbier A, Jaffar-Bandjee M, Gasque P (2012) Arthritogenic alphaviruses—an overview. Nat Rev Rheumatol 8(7):420429. doi:10.1038/nrrheum.2012.64 CrossRef

Staples J, Breiman R, Powers A (2009) Chikungunya fever: an epidemiological review of a re-emerging infectious disease. Clin Infect Dis 49(6):942–948. doi:10.1086/605496 CrossRefPubMed

Ávila MA, Vilá LM (2015) Rheumatic manifestations in patients with chikungunya infection. P R Health Sci J 34(2):71–77

Pineda C, Muñoz-Louis R, Caballero-Uribe CV, Viasus D (2016) Chikungunya in the region of the Americas. A challenge for rheumatologists and health care systems. Clin Rheumatol 35(10):2381–2385. doi:10.1007/s10067-016-3390-y CrossRefPubMed

Yactoyo S, Staples JE, Millot V, Cibrelus L, Pardo PR (2016) Epidemiology of chikungunya in the Americas. J Infect Dis 214(5):441–445. doi:10.1093/infdis/jiw390 CrossRef

Feldstein LR, Ellis EM, Rowhani-Rahbar A, Halloran ME, Ellis BR (2016) The first reported outbreak of chikungunya in the U.S. Virgin Islands, 2014-2015. Am J Trop Med Hyg 95(4):885–889. doi:10.4269/ajtmh.16-0288 CrossRefPubMedPubMedCentral

Thiberville S, Moyen N, Dupuis-Maguiraga L, Nougairede A, Gould EA, Roques P, De Lamballerie X (2013) Chikungunya fever: epidemiology, clinical syndrome, pathogenesis and therapy. Antivir Res 99(3):345–370. doi:10.1016/j.antiviral.2013.06.009 CrossRefPubMed

Ng LF, Chow A, Sun Y, Kwek DJ, Lim P, Dimatatac F et al (2009) IL-1β, IL-6, and RANTES as biomarkers of chikungunya severity. PLoS One 4(1):e4261. doi:10.1371/journal.pone.0004261 CrossRefPubMedPubMedCentral

Chow A, Her Z, Ong EK, Chen J, Dimatatac F, Kwek DJ et al (2010) Persistent arthralgia induced by chikungunya virus infection is associated with interleukin-6 and granulocyte macrophage colony stimulating factor. J Infect Dis 203(2):149–157. doi:10.1093/infdis/jiq042 CrossRef

10.

Miossec P, Korn T, Kuchroo VK (2009) Interleukin17 and type 17 helper T cells. N Engl J Med 361(9):888–898. doi:10.1056/nejmra0707449 CrossRefPubMed

11.

Chen W, Foo S, Rulli NE, Taylor A, Sheng K, Herrero LJ et al (2014) Arthritogenic alphaviral infection perturbs osteoblast function and triggers pathologic bone loss. Proc Natl Acad Sci 111(16):6040–6045. doi:10.1073/pnas.1318859111 CrossRefPubMedPubMedCentral

12.

Simon F, Javelle E, Oliver M, Goffart IL, Marimoutou C (2011) Chikungunya virus infection. Curr Infect Dis Rep 13:218–228. doi:10.1007/s11908-011-0180-1 CrossRefPubMedPubMedCentral

13.

Couderc T, Chrétien F, Schilte C, Disson O, Brigitte M, Guivel-Benhassine F et al (2008) A mouse model for chikungunya: young age and inefficient type-I interferon signaling are risk factors for severe disease. PLoS Pathog 4(2):e29. doi:10.1371/journal.ppat.0040029 CrossRefPubMedPubMedCentral

14.

Malvy D, Ezzedine K, Mamani-Matsuda M, Autran B, Tolou H, Receveur M et al (2009) Destructive arthritis in a patient with chikungunya virus infection with persistent specific IgM antibodies. BMC Infect Dis 9(1). doi:10.1186/1471-2334-9-200

15.

Reddy V, Desai A, Krishna SS, Vasanthapuram R (2017) Molecular mimicry between chikungunya virus and host components: a possible mechanism for the arthritic manifestations. PLoS Negl Trop Dis 11(1):e0005238. doi:10.1371/journal.pntd.0005238 CrossRefPubMedPubMedCentral

16.

Goupil BA, Mores CN (2016) A review of chikungunya virus-induced arthralgia: clinical manifestations, therapeutics, and pathogenesis. Open Rheumatol J 10:129–140. doi:10.2174/1874312901610010129 PubMedPubMedCentral

17.

World Health Organization (2008) Guidelines on clinical management of Chikungunya Fever. Retrieved from South-East Asia Regional Office of WHO website: http://www.wpro.who.int/mvp/topics/ntd/Clinical_Mgnt_Chikungunya_WH O_SEARO.pdf

18.

Ferreira-Sarmiento S, Lastra-Terán KP, De la Rosa D, Viasus D (2015) Severe chikungunya virus infection. Salud Uninorte 31(3):631–641. doi:10.14482/sun.31.3.7352 CrossRef

19.

Pinheiro TJ, Guimarães LF, Silva MT, Soares CN (2016) Neurological manifestations of chikungunya and Zika infections. Arquivos de NeuroPsiquiatria 74(11):937–943. doi:10.1590/0004282x20160138 CrossRef

20.

Sepúlveda-Delgado J, Vera-Lastra OL, Trujillo-Murillo K, Canseco-Avila LM, Sánchez-González RA, Gómez-Cruz O et al (2017) Inflammatory biomarkers, disease activity index, and self-reported disability may be predictors of chronic arthritis after chikungunya infection: brief report. Clin Rheumatol. doi:10.1007/s10067-0163419-2

21.

Rodriguez-Morales AJ, Gil-Restrepo AF, RamírezJaramillo V, Montoya-Arias CP, AcevedoMendoza WF, Bedoya-Arias JE et al (2016) Post-chikungunya chronic inflammatory rheumatism: results from a retrospective follow-up study of 283 adult and child cases in La Virginia, Risaralda, Colombia. F1000Res 5:360. doi:10.12688/f1000research.8235 CrossRefPubMedPubMedCentral

22.

Mathew AJ, Goyal V, George E, Thekkemuriyil DV, Jayakumar B, Chopra A (2011) Rheumatic-musculoskeletal pain and disorders in a naïve group of individuals 15 months following a chikungunya viral epidemic in south India: a population based observational study. Int J Clin Pract 65(12):1306–1312. doi:10.1111/j.1742-1241.2011.02792.x CrossRefPubMed

23.

Feldstein LR, Rowhani-Rahbar A, Staples JE, Weaver MR, Halloran ME, Ellis EM (2017) Persistent arthralgia associated with chikungunya virus outbreak, US Virgin Islands, December 2014–February 2016. Emerg Infect Dis 23(4):673–676. doi:10.3201/eid2304.161562 CrossRefPubMedPubMedCentral

24.

Kennedy AC, Fleming J, Solomon L (1980) Chikungunya viral arthropathy: a clinical description. J Rheumatol 7(2):231–236PubMed

25.

Javelle E, Ribera A, Degasne I, Gaüzère B, Marimoutou C, Simon F (2015) Specific management of post-chikungunya rheumatic disorders: a retrospective study of 159 cases in Reunion Island from 2006-2012. PLoS Negl Trop Dis 9(3):e0003603. doi:10.1371/journal.pntd.000360 CrossRefPubMedPubMedCentral

26.

Schilte C, Staikovsky F, Couderc T, Madec Y, Carpentier F, Kassab S et al (2013) Correction: chikungunya virus-associated long-term arthralgia: a 36-month prospective longitudinal study. PLoS Negl Trop Dis 7(3). doi:10.1371/annotation/850ee20f-2641-46ac-b0c6ef4ae79b6de6

27.

Essackjee K, Goorah S, Ramchurn SK, Cheeneebash J, Walker-Bone K (2013) Prevalence of and risk factors for chronic arthralgia and rheumatoid-like polyarthritis more than 2 years after infection with chikungunya virus. Postgrad Med J 89(1054):440–447. doi:10.1136/postgradmedj-2012-131477 CrossRefPubMed

28.

Miner JJ, Aw Yeang HX, Fox JM, Taffner S, Malkova ON, Oh ST et al (2015) Brief report: chikungunya viral arthritis in the United States: a mimic of seronegative rheumatoid arthritis. Arthritis Rheumatol 67(5):1214–1220. doi:10.1002/art.39027 CrossRefPubMedPubMedCentral

29.

Krutikov M, Manson J (2016) Chikungunya virus infection: an update on joint manifestations and management. Rambam Maimonides Med J 7(4):e0033. doi:10.5041/rmmj.10260 CrossRefPubMedCentral

30.

Abdelnabi R, Neyts J, Delang L (2017) Chikungunya virus infections: time to act, time to treat. Curr Opin Virol 24:25–30

31.

Antunes de Brito CA, Arraes von Sohsten AK, De Sá Leitão CC, de Brito CM, De Azevedo RC, Valadares LD, Magnata da Fonte CA et al (2016) Pharmacologic management of pain in patients with chikungunya: a guideline. Rev Soc Bras Med Trop 49(6):668–679CrossRef

32.

In Okeoma CM (2016) Chikungunya virus: advances in biology, pathogenesis, and treatment

33.

Simon F, Javelle E, Cabie A, Bouquillard E, Troisgros O, Gentile G et al (2015) French guidelines for the management of chikungunya (acute and persistent presentations). November 2014. Med Mal Infect 45(7):243–263. doi:10.1016/j.medmal.2015.05.007 CrossRefPubMed

34.

Hoarau JJ, Jaffar Bandjee MC, Krejbich Trotot P, Das T, Li-Pat-Yuen G, Dassa B et al (2010) Persistent chronic inflammation and infection by chikungunya arthritogenic alphavirus in spite of a robust host immune response. J Immunol 184(10):5914–5927. doi:10.4049/jimmunol.0900255 CrossRefPubMed

35.

Gérardin P, Fianu A, Michault A, Mussard C, Boussaïd K, Rollot O et al (2013) Predictors of chikungunya rheumatism: a prognostic survey ancillary to the TELECHIK cohort study. Arthritis Res Ther 15(1):R9. doi:10.1186/ar4137 CrossRefPubMedPubMedCentral

36.

Foissac M, Javelle E, Ray S, Guérin B, Simon F (2015) Post-chikungunya rheumatoid arthritis, Saint Martin. Emerg Infect Dis 21(3):530–532. doi:10.3201/eid2103.141397 CrossRefPubMedPubMedCentral

37.

Horcada ML, Díaz-Calderón C, Garrido L (2015) Fiebre chikungunya. Manifestaciones reumáticas de una infección emergente en Europa. Reumatología Clínica 11(3):161–164. doi:10.1016/j.reuma.2014.07.005 CrossRefPubMed

38.

Chopra A, Anuradha V, Lagoo-Joshi V, Kunjir V, Salvi S, Saluja M (2008) Chikungunya virus aches and pains: an emerging challenge. Arthritis Rheum 58(9):2921–2922. doi:10.1002/art.23753 CrossRefPubMed

39.

Sebastian MR, Lodha R, Kabra S (2009) Chikungunya infection in children. The Indian Journal of Pediatrics 76(2):185–189. doi:10.1007/s12098-009-0049-6 CrossRefPubMed

40.

Chopra A, Saluja M, Venugopalan A (2014) Effectiveness of chloroquine and inflammatory cytokine response in patients with early persistent musculoskeletal pain and arthritis following chikungunya virus infection. Arthritis Rheumatol 66(2):319–326. doi:10.1002/art.38221 CrossRefPubMed

41.

Ravindran V, Alias G (2016) Efficacy of combination DMARD therapy vs. hydroxychloroquine monotherapy in chronic persistent chikungunya arthritis: a 24-week randomized controlled open label study. Clinical Rheumatol. doi:10.1007/s10067-016-3429-0

42.

Simon F, Parola P, Grandadam M, Fourcade S, Oliver M, Brouqui P et al (2007) Chikungunya infection. Medicine 86(3):123–137. doi:10.1097/md/0b013e31806010a5 CrossRefPubMed

43.

Sissoko D, Malvy D, Ezzedine K, Renault P, Moscetti F, Ledrans M, Pierre V (2009) Post epidemic chikungunya disease on Reunion Island: course of rheumatic manifestations and associated factors over a 15-month period. PLoS Negl Trop Dis 3(3):e389. doi:10.1371/journal.pntd.0000389 CrossRefPubMedPubMedCentral

44.

Padmakumar B, Jayan JB, Menon RM, Krishnankutty B, Payippallil R, Nisha R (2009) Comparative evaluation of four therapeutic regimes in chikungunya arthritis: a prospective randomized parallel group study. Indian J Rheumatol 4(3):94–101. doi:10.1016/s0973-3698(10)60189-6 CrossRef

45.

Blettery M, Brunier L, Polomat K, Moinet F, Deligny C, Arfi S, Jean-Baptiste G, De Brandt M (2016) Brief report: management of chronic post-chikungunya rheumatic disease: the Martinican experience. Arthritis Rheumatol 68(11):2817–2824. doi:10.1002/art.39775 CrossRefPubMed

46.

Rosario V, Munoz-Louis R, Valdez T, Adames S, Medrano J, Paulino I, Paula J, Alba- Fériz, R. (2015) Chikungunya infection in the general population and in patients with rheumatoid arthritis on biological therapy. Clin Rheumatol. doi:10.1007/s10067-015-2979-x

47.

Chan ESL, Cronstein BN (2002) Molecular action of methotrexate in inflammatory diseases. Arthritis Res, 4(4), 266–273

48.

Swierkot J, Szechinski J (2006) Methotrexate in rheumatoid arthritis. Pharmacol Rep 58:473–492PubMed

49.

Ganu MA, Ganu AS (2011) Post-chikungunya chronic arthritis—our experience with DMARDs over two year follow up. J Assoc Physicians India 59:83–86PubMed

50.

McInnes IB, Schett G (2011) The pathogenesis of rheumatoid arthritis. N Engl J Med 365(23):2205–2219CrossRefPubMed

51.

Donahue KE, Jonas DE, Hansen RA, Roubey R, Jonas B, Lux LJ, …, Gartlehner G (2012) Drug therapy for rheumatoid arthritis in adults: an update. Agency for Healthcare Research and Quality (US), 55. Retrieved from http://effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productid=1042

52.

Marimoutou C, Ferraro J, Javelle E, Deparis X, Simon F (2015) Chikungunya infection: self-reported rheumatic morbidity and impaired quality of life persist 6 years later. Clin Microbiol Infect 21(7):688–693. doi:10.1016/j.cmi.2015.02.024 CrossRefPubMed

53.

Chaaithanya IK, Muruganandam N, Raghuraj U, Sugunan AP, Rajesh R, Anwesh M et al (2014) Chronic inflammatory arthritis with persisting bony erosions in patients following chikungunya infection. Indian J Med Res 140(1):142–145 Retrieved March 10, 2017PubMedPubMedCentral

Titel: Management of chikungunya arthritis
verfasst von: J. Kennedy Amaral Pereira
Robert T. Schoen
Publikationsdatum: 03.08.2017
Verlag: Springer London
Erschienen in: Clinical Rheumatology / Ausgabe 10/2017
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-017-3766-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2017

Disease activity, handgrip strengths, and hand dexterity in patients with rheumatoid arthritis

Multiple values of 18F-FDG PET/CT in idiopathic inflammatory myopathy

Tumor necrosis factor-α -308 polymorphism in North Indian rheumatoid arthritis patients and association with mRNA and serum TNF-α

Group-based exercise at workplace: short-term effects of neck and shoulder resistance training in video display unit workers with work-related chronic neck pain—a pilot randomized trial

Intramuscular clodronate in erosive osteoarthritis of the hand is effective on pain and reduces serum COMP: a randomized pilot trial—The ER.O.D.E. study (ERosive Osteoarthritis and Disodium-clodronate Evaluation)

Serum levels of the bone turnover markers dickkopf-1, osteoprotegerin, and TNF-α in knee osteoarthritis patients